These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23382923)

  • 1. Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.
    Hawse JR; Subramaniam M; Cicek M; Wu X; Gingery A; Grygo SB; Sun Z; Pitel KS; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC
    PLoS One; 2013; 8(1):e54613. PubMed ID: 23382923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
    Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
    Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
    Jones CJ; Subramaniam M; Emch MJ; Bruinsma ES; Ingle JN; Goetz MP; Hawse JR
    Mol Cancer Res; 2021 Jun; 19(6):1026-1039. PubMed ID: 33627502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
    Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
    Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
    Lim YC; Desta Z; Flockhart DA; Skaar TC
    Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
    Jayaraman S; Reid JM; Hawse JR; Goetz MP
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
    Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
    Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
    Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.
    Nehra R; Riggins RB; Shajahan AN; Zwart A; Crawford AC; Clarke R
    FASEB J; 2010 Jun; 24(6):2040-55. PubMed ID: 20154269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
    Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
    Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
    de Vries Schultink AH; Alexi X; van Werkhoven E; Madlensky L; Natarajan L; Flatt SW; Zwart W; Linn SC; Parker BA; Wu AH; Pierce JP; Huitema AD; Beijnen JH
    Breast Cancer Res Treat; 2017 Feb; 161(3):567-574. PubMed ID: 28005246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.
    Kansra S; Yamagata S; Sneade L; Foster L; Ben-Jonathan N
    Mol Cell Endocrinol; 2005 Jul; 239(1-2):27-36. PubMed ID: 15950373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERE-independent ERalpha target genes differentially expressed in human breast tumors.
    Glidewell-Kenney C; Weiss J; Lee EJ; Pillai S; Ishikawa T; Ariazi EA; Jameson JL
    Mol Cell Endocrinol; 2005 Dec; 245(1-2):53-9. PubMed ID: 16298037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.
    Kretzer NM; Cherian MT; Mao C; Aninye IO; Reynolds PD; Schiff R; Hergenrother PJ; Nordeen SK; Wilson EM; Shapiro DJ
    J Biol Chem; 2010 Dec; 285(53):41863-73. PubMed ID: 21041310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen induction of CCAAT enhancer-binding protein alpha is required for tamoxifen-induced apoptosis.
    Cheng J; Yu DV; Zhou JH; Shapiro DJ
    J Biol Chem; 2007 Oct; 282(42):30535-43. PubMed ID: 17716978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen metabolite endoxifen interferes with the polyamine pathway in breast cancer.
    Thomas TJ; Thomas T; John S; Hsu HC; Yang P; Keinänen TA; Hyvönen MT
    Amino Acids; 2016 Oct; 48(10):2293-302. PubMed ID: 27438264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
    Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.